Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)

ConditionHemostasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire Dijon

About this trial

The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.

Eligibility criteria

Qualifiers

Person having given their non-opposition

Person of legal age

Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).

Disqualifiers

persons under legal protection (curatorship, guardianship)

persons subject to a court protection order

pregnant, parturient or breast-feeding women

adult incapable or unable to give consent

Trial design

Treatments tested in this trial

  • Sampling of 3 additional BAPA tubes

Treatment groups

100 Participants
are divided into 1 treatment group